Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Daniels

Physician Assistant, Medical Baltimore, MD Physician Assistant

NPI 1063714475 CMS profile 10414110

4660 Wilkens Ave Ste 302, Baltimore, MD 21229

Open in the dashboard

General payments

$8,626

460 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Daniels of Baltimore, MD is reported in the CMS Open Payments database as having received $8,626 across 460 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,328 58
2024 General $2,099 101
2023 General $1,713 96
2022 General $1,732 108
2021 General $1,754 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Daniels
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Michelle Daniels were reported at $1,328. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Michelle Daniels Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,754 $156 $41–$563 $132
2022 $1,732 $185 $55–$649 $149
2023 $1,713 $199 $58–$717 $160
2024 $2,099 $206 $62–$740 $164
2025 $1,328 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,362 71 payments
  2. Collegium Pharmaceutical, Inc. $1,319 91 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,087 93 payments
  4. Abbott Laboratories $501 16 payments
  5. Pfizer Inc. $413 17 payments
  6. Saluda Medical Americas, Inc. $411 13 payments
  7. Nevro Corp. $371 13 payments
  8. Boston Scientific Corporation $332 12 payments
  9. Protega Pharmaceutials LLC $301 15 payments
  10. Lundbeck LLC $286 15 payments
  11. Other $2,242 104 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,626 460 payments
Products named General payments · program years 2021–2025
  1. RELISTOR $1,087 93 payments
  2. UBRELVY $946 51 payments
  3. XTAMPZA $776 58 payments
  4. BELBUCA $520 31 payments
  5. Evoke $411 13 payments
  6. Qutenza $393 15 payments
  7. NURTEC ODT Pain $378 15 payments
  8. NURTEC ODT Primary Care $310 12 payments
  9. ROXYBOND $301 15 payments
  10. Omnia $286 10 payments
  11. Other $3,858 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

7,352

Median for Physician Assistant: 241

Drug cost

$434,545

Median for Physician Assistant: $4,110

Branded share of claims

25.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Percocet Oxycodone Hcl/Acetaminophen Brand 13 $57,639
Relistor Methylnaltrexone Bromide Brand 21 $49,735
Xtampza Er Oxycodone Myristate Brand 131 $45,406
Oxycodone Hcl Generic 2,007 $34,513
Nucynta Tapentadol Hcl Brand 26 $34,456
Belbuca Buprenorphine Hcl Brand 42 $30,296
Oxycontin Oxycodone Hcl Brand 76 $27,913
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 677 $17,545
Pregabalin Generic 390 $16,715
Buprenorphine Generic 53 $13,891

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$118,123

Of which drugs: $284

Medicare patients

261

Average age 65

Services billed

1,376

190 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 47%
Depression 38%
COPD 31%
Chronic kidney disease 25%
Ischemic heart disease 21%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $260
$260 21 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $158
$158 131 —
BELBUCA
  • Collegium Pharmaceutical, Inc. $152
$152 42 —
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $94
$94 — —
NURTEC ODT
  • PFIZER INC. $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

460 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record